Section review - Central & peripheral nervous systems: Tachykinin antagonists in development
Expert Opinion on Investigational Drugs, ISSN: 1354-3784, Vol: 4, Issue: 4, Page: 299-311
1995
- 14Citations
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations14
- Citation Indexes14
- 14
- CrossRef9
Article Description
The literature on tachykinin antagonists published during the second semester of 1994 is reviewed with emphasis on the potential clinical indications for antagonists of the three neurokinin receptor families, namely NK, NK and NK. For each therapeutic domain, particular attention is given to the development of adequate experimental animal models needed to evaluate new compounds in vitro and in vivo. Finally, recent developments in the molecular biology of NK receptors and design of new non-peptide NK antagonists are presented. 1995 © Ashley Publications Ltd.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know